biostudies-literatureEngelen MMFonds Wetenschappelijk Onderzoeke12826https://www.ebi.ac.uk/biostudies/studies/S-EPMC9618401biostudies-literatureUnknown6(7)<h4>Background</h4>Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID-19 patients.<h4>Methods</h4>In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients hospitalized with COVID-19 were 1:2 randomized to receive standard of care (SOC) or SOC plus study intervention. The intervention consisted of aprotinin (2,000,000 IE IV four times daily) combined with low molecular weight heparin (LMWH; SC 50 IU/kg twice daily on the ward, 75 IU/kg twice daily in intensive care). Additionally, patients with predefined hyperinflammation received the interleukin-1 Research and practice in thrombosis and haemostasisModulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study.PMC9618401G0G4720NHeytens LDe Tavernier BCeunen HVan Thillo QWouters CRobberecht WDupont LRuttens DLiesenborghs LDolhain JEngelen MMVan Wijngaerden EVos RServaes VWauters JMeyfroidt GHoppenbrouwers MWens KVandenbriele CCludts KGunst JNeyts JSpalart VMesotten DSpriet IVan den Berghe GDevos TJacobs CDauwe DJanssens WMeersseman PRoebroek DClaes KBelmans AVan Geet CSmet NDevooght CDaems KRex SVerhamme PDe Munter PThomeer MBetrains AVerbeke GFivez TDreesen PVanassche TOckerman AMartens CPDebaveye BD'hondt MWilmer ADAWn Consortium MembersDapper IVanheule KTuyls SGyselinck IfalseModulation of thromboinflammation in hospitalized COVID-19 patients with aprotinin, low molecular weight heparin, and anakinra: The DAWn-Antico study.<h4>Background</h4>Thromboinflammation plays a central role in severe COVID-19. The kallikrein pathway activates both inflammatory pathways and contact-mediated coagulation. We investigated if modulation of the thromboinflammatory response improves outcomes in hospitalized COVID-19 patients.<h4>Methods</h4>In this multicenter open-label randomized clinical trial (EudraCT 2020-001739-28), patients hospitalized with COVID-19 were 1:2 randomized to receive standard of care (SOC) or SOC plus study intervention. The intervention consisted of aprotinin (2,000,000 IE IV four times daily) combined with low molecular weight heparin (LMWH; SC 50 IU/kg twice daily on the ward, 75 IU/kg twice daily in intensive care). Additionally, patients with predefined hyperinflammation received the interleukin-1 2022-01-01T00:00:00Z2022 Oct2026-05-27T20:42:27.033Z2026-04-08T01:48:54.355ZS-EPMC96184013632483110.1002/rth2.12826